Clinical Trial Update: Persistence of Antibodies in Children Aged 7 to 15 Years Who Previously Received One Dose of Menactra® or Menomune® [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the persistence of antibodies in children aged 7 to 15 years after a single dose of Menactra or Menomune; results were completed and po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningitis
• Meningococcal Infection

Drugs mentioned

• Menactra (Meningococcal conjugate vaccine (A, C, W, Y))
• Menomune (Meningococcal polysaccharide vaccine (serogroups A, C, W, Y))

Snippet

Sponsor: Sanofi Pasteur, a Sanofi Company | Conditions: Meningitis, Meningococcal Infection | Phase 2 | Status: COMPLETED | Results posted: 2009-11-25